- Trial phase
- Phase 3
- Time to market
- If ECLIPSE 1 data is positive, Vir could file for regulatory approval in 2027, with potential FDA decision in 2028. The program has FDA Breakthrough Therapy and EMA PRIME designations, which could accelerate review.
- Why 8/10
- The single next hard, dated catalyst is the Phase 3 ECLIPSE 1 topline data presentation at AASLD on November 8, 2026 (tomorrow), with an investor call on November 9. This is a pivotal readout for Vir's lead hepatitis delta program, which drives most of the company's near-term valuation. The company also has an oncology pipeline and Gilead collaboration, so it is not a pure single-asset binary, but the hepatitis delta program is clearly the dominant value driver.
The pivotal Phase 3 ECLIPSE 1 topline data is being presented at AASLD on November 8, 2026 (tomorrow), with an investor call on November 9 at 8:30 AM ET. Positive results showing non-inferiority or superiority versus bulevirtide/deferred treatment could drive significant upside given the $21 mean analyst price target (90%+ implied upside). Negative or mixed data would likely pressure the stock given the program's centrality to Vir's valuation. ECLIPSE 2 and ECLIPSE 3 readouts are expected in Q1 2027.
Price Chart
Executive Summary
Tobevibart (VIR-3434) is Vir Biotechnology's investigational monoclonal antibody targeting hepatitis B surface antigen (HBsAg), being developed in combination with elebsiran (VIR-2218, an siRNA) primarily for chronic hepatitis delta (CHD). Phase 2 SOLSTICE data published in NEJM showed 66% of patients achieved undetectable HDV RNA at week 48 with a favorable safety profile. The pivotal Phase 3 ECLIPSE 1 topline results are being presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Gilead's Hepcludex (bulevirtide) was FDA-approved in May 2026 as the first CHD treatment, creating a competitive landscape, but tobevibart+elebsiran offers a potentially more convenient monthly subcutaneous regimen versus daily injections. Vir ended Q3 2026 with ~$901M in cash (plus $90M Gilead upfront), funding operations into H2 2028.
How It Works
Tobevibart is a lab-made antibody that grabs onto a protein (HBsAg) on the surface of hepatitis B and hepatitis delta viruses. This blocks the viruses from entering liver cells and helps the immune system clear viral particles from the blood. It is given as a monthly shot under the skin and is paired with elebsiran, an RNA-targeting drug that silences viral protein production.
Trial Status
The pivotal Phase 3 ECLIPSE 1 trial (NCT06903338, 124 patients enrolled) evaluating tobevibart + elebsiran versus deferred treatment in chronic hepatitis delta has completed enrollment and topline primary endpoint results are being presented at AASLD on November 8, 2026. Two additional Phase 3 trials are ongoing: ECLIPSE 2 (switch study in patients not suppressed on bulevirtide) and ECLIPSE 3 (head-to-head versus bulevirtide), with data expected in Q1 2027. Phase 2 SOLSTICE data published in NEJM showed 66% of combination patients achieved undetectable HDV RNA at week 48 with no grade 3+ treatment-related adverse events.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ECLIPSE 1 topline data presentation at AASLD on November 8, 2026
- Investor conference call on November 9, 2026 at 8:30 AM ET
- ECLIPSE 2 and ECLIPSE 3 Phase 3 readouts expected in Q1 2027
- Potential regulatory submission if ECLIPSE data is positive
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vir Biotechnology, Inc. 8-K VIR ·Originating report